Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Wes Lepla advises on all aspects of European competition law, including merger control, cartels, anticompetitive agreements, abuse of a dominant position, and state aid law.

He has worked on a range of merger control cases before the European Commission and numerous national authorities and has gained extensive experience in coordinating multijurisdictional merger control notifications and proceedings. Mr. Lepla has represented clients in antitrust proceedings and regularly counsels on vertical agreements and the licensing of intellectual property rights.


  • Illumina in its $1.2 billion acquisition of Pacific Biosciences.
  • Northrop Grumman in its $9.2 billion acquisition of Orbital ATK.
  • Verizon in its $4.5 billion acquisition of Yahoo.
  • Mexichem in its $1.8 billion acquisition of Netafim.
  • Emergent BioSolutions in its $270 million acquisition of PaxVax.
  • Central European Media Enterprises in the sale of its broadcast operations in Croatia and Slovenia to Slovenia Broadband for $262 million.
  • A global manufacturer of consumable dental products regarding a multi-billion acquisition (cleared by the European Commission in Phase I with remedies).
  • A global pharmaceutical company on the largest pharmaceutical merger ever (eventually abandoned).
  • One of the world’s largest FMCG companies regarding numerous of its global transactions, including in connection with the divestment of its personal power business, pet care business, bleach business, and several fragrance and soap businesses. 


  • Advising a pharmaceutical company on an investigation by the CMA under Chapters I and II of the Competition Act and Articles 101 and 102 TFEU.
  • Represented a major financial institution in relation to the European Commission’s antitrust investigation into credit default swaps.
  • Advised a financial institution on a potential investigation under Article 101 TFEU.
  • Advised pharmaceutical companies on Article 101 and 102 TFEU issues.
  • Counseled on the licensing of IP and the legality of vertical agreements.

Previous Experience

  • Research and Teaching Assistant, Free University of Brussels (VUB) (2014-2019)
  • Fellowship for Graduate Study, Belgian American Educational Foundation (B.A.E.F) (2012-2013)
  • Fulbright Scholar, Commission for Educational Exchange Between the United States of America, Belgium and Luxembourg, The Fulbright Program (2012-2013)
  • René Marcq Award, Free University of Brussels (VUB) (2012)